Molecular Interaction Study between Gentamicin and the Cancer Protein Target (TP53) using in silico Tools

Priyadharshini M. *

PG and Research Department of Zoology, Ethiraj College for Women, Chennai, 600 008, India.

D. Leelavathi

PG and Research Department of Zoology, Ethiraj College for Women, Chennai, 600 008, India.

Tanzeem Azeeza S.

PG and Research Department of Zoology, Ethiraj College for Women, Chennai, 600 008, India.

*Author to whom correspondence should be addressed.


Abstract

The most prevalent mutation in hepatocellular carcinoma (HCC), TP53 mutations impacts the course and prognosis of HCC. 3D in silico drug docking techniques were employed to make the possible mutant target tumor protein 53 (TP53) interact with benzene acetic acid (Gentamicin) and non-steroidal anti-inflammatory drugs (NSAIDs). To carry out drug docking techniques, the translated amino acid sequence and three-dimensional chemical compound were obtained from the NCBI database. The use of sophisticated 3D molecular visualization tools was employed in post-docking experiments. The docking study results unequivocally show that gentamicin directly suppresses amino acid mutational sites. TP53 and Gentamicin's electrostatic force is depicted in a three-dimensional manner using notions from molecular dynamics techniques. In the end, it was determined that gentamicin, an Antibiotic medication, helps treat liver cancer. Most chemotherapy medications cause pain. Therefore, Gentamicin shall be used to lessen discomfort while minimizing the symptoms of cancer.

Keywords: Hepatocellular carcinoma, tumor protein 53, gentamicin and drug docking


How to Cite

Priyadharshini M., Leelavathi , D., & Tanzeem Azeeza S. (2024). Molecular Interaction Study between Gentamicin and the Cancer Protein Target (TP53) using in silico Tools. UTTAR PRADESH JOURNAL OF ZOOLOGY, 45(3), 233–240. https://doi.org/10.56557/upjoz/2024/v45i33897

Downloads

Download data is not yet available.

References

Muddu VK, Bonda A. Hepatocellular carcinoma in India: Time for a new focus. Cancer Research, Statistics, and Treatment. 2023;6(3):449. Available:https://doi.org/10.4103/crst.crst_277_23

Garrido A, Djouder N. Cirrhosis: A Questioned risk factor for hepatocellular carcinoma. Trends in Cancer. 2021; 7(1):29–36. Available:https://doi.org/10.1016/j.trecan.2020.08.005

Panneerselvam S, Wilson C, Kumar P, Abirami D, Pamarthi J, Reddy MS, Varghese J. (n.d.). Overview of hepatocellular carcinoma: From molecular aspects to future therapeutic options. Cell Adhesion & Migration, 17(1), 1–21. Available:https://doi.org/10.1080/19336918.2023.2258539

Qu J, Lu W, Chen M, Gao W, Zhang C, Guo B, Yang J. Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer. Experimental and Therapeutic Medicine. 2020;20(5):1–1. Available:https://doi.org/10.3892/etm.2020.9145

Yu S, Ji G, Zhang L. The role of p53 in liver fibrosis. Frontiers in Pharmacology. 2022;13. Available:https://www.frontiersin.org/articles/10.3389/fphar.2022.1057829

Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental & Clinical Cancer Research. 2018;37(1):30. Available:https://doi.org/10.1186/s13046-018-0705-7

Wu Q, Zhang K, Jiang S, Fu L, Shi Y, Tan R, Cui J, Zhou Y. A key protein that regulates pulmonary fibrosis. Oxidative Medicine and Cellular Longevit. 2020; 53. Available:https://www.hindawi.com/journals/omcl/2020/6635794/

Chaves BJ, Tadi P. Gentamicin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [Accessed on 2023 Apr 10] PMID: 32491482

Block M, Blanchard DL. Aminoglycosides. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [Accessed on 2023 Jul 17] PMID: 31082149

Lin LL, Hung JN, Shiu SI, Su YH, Chen WC, Tseng JJ. Efficacy of prophylactic antibiotics for preterm premature rupture of membranes: A systematic review and network meta-analysis. Am J Obstet Gynecol MFM. 2023;5(7):100978. DOI: 10.1016/j.ajogmf.2023.100978 [Accessed on 2023 Apr 23] PMID: 37094635

Baradaran-Heravi A, Niesser J, Balgi AD, Choi K, Zimmerman C, South AP, Anderson HJ, Strynadka NC., Bally MB, Roberge M. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Proceedings of the National Academy of Sciences. 2017;114(13):3479–3484. Available:https://doi.org/10.1073/pnas.1620982114

Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S. Genomic analysis revealed new oncogenic signatures in TP53-Mutant Hepatocellular Carcinoma. Frontiers in Genetics. 2018;9. Available:https://www.frontiersin.org/articles/10.3389/fgene.2018.00002

Sunghwan Kim, Jie Chen, Tiejun Cheng, Asta Gindulyte, Jia He, Siqian He, Qingliang Li, Benjamin A Shoemaker, Paul A Thiessen, Bo Yu, Leonid Zaslavsky, Jian Zhang, Evan E Bolton, Pub Chem in 2021: New data content and improved web interfaces, Nucleic Acids Research. 2021;49(D1):D1388–D1395. Available:https://doi.org/10.1093/nar/gkaa971

National Cancer Institute, Online SMILES Translator Available:https://cactus.nci.nih.gov/translate/index.html

Yan Y, Tao H, He J, et al. The HDOCK server for integrated protein–protein docking. Nat Protoc. 2020;15:1829–1852. Available:https://doi.org/10.1038/s41596-020-0312-x

Voskarides K, Giannopoulou N. The role of TP53 in adaptation and evolution. Cells. 2023;12(3):512. DOI: 10.3390/cells12030512 PMID: 36766853; PMCID: PMC9914165

Sakaguchi S, Nakagawa N, Wahba HM, Wada J, Kamada R, Omichinski JG, Sakaguchi K. Highly similar tetrameri-zation domains from the p53 protein of different mammalian species possess varying biophysical, Functional and structural properties. Int J Mol Sci. 2023; 24(23):16620. DOI: 10.3390/ijms242316620 PMID: 38068946; PMCID: PMC10706167

Zhang Y, Zhao Z, Li W, Tang Y, Wang S. Mechanism of taxanes in the treatment of lung cancer based on network pharmacology and molecular docking. Curr Issues Mol Biol. 2023;45(8):6564-6582. DOI: 10.3390/cimb45080414 PMID: 37623233; PMCID: PMC10453041

Houseini ST, Nemati F, Sattari A, Azadeh M, BishehKolaei R. Design of crRNA to regulate MicroRNAs related to metastasis in colorectal cancer using CRISPR-C2c2 (Cas13a) Technique. Cell J. 2023;25 (5):354-362. DOI: 10.22074/cellj.2023.1989121.1223 PMID: 37300297; PMCID: PMC10257061

Astalakshmi P, Basheera John M, Kavinilavu G, Vimala D. Identification of the efficiency of Pentane on the bacterial and insecticide proteins of Aedes aegypti and Aeromonas hydrophila by Insilico methods. Int. J. Mosq Res. 2023;10 (3):47-53.

Astalakshmi P, Basheera John M, Kavinilavu G, Vimala D. In silico study on Hexadecanoic acid against the outer membrane protein transport protein of Culex quinquefasciatus and Aeromonas hydrophila. Int J Mosq Res 2023;10 (4):07-14.

Nijanthi P, Santhi S, Balaji Munivelan. Molecular dynamics studies on the arginine kinase protein of Aedes sollicitans: Against the natural chemical compound, Gedunin. Int J Mosq Res 2023;10(2):10-14.

Maithreyee S1, Prabha V1, Molecular interactions between anti-inflammatory drug with colorectal cancer (MSH2) Protein Using In-silico Studies. Solovyov Studies ISPU. 2023;71(10).

Nithya G, Prabha V. Identification of a plant derivative (Hibiscus cannabinus) for mosquito (Anopheles darlingi) control using in silico protein-protein docking techniques. Int J Mosq Res. 2023; 10(4):25-29.

Balaji Munivelan. Identification of the mutated sites present in the transmembrane regions of SCN1A_ HUMAN (Sodium Voltage-Gated Channel Alpha Subunit 1) using Insilico techniques. Int. J Pharm. Int. Biosci. 2020;5(1):1-6.

Suganya M, Brindha Devi GB. Comparative study on the effect of the insecticide, Phorate on the COI (Cytochrome oxidase subunit 1) of Eudrilus eugeniae and Aedes aegypti using in silico techniques. Int J Mosq Res. 2023;10(6):39-44.

Hassin O, Oren M. Drugging p53 in cancer: One protein, many targets. Nat Rev Drug Discov. 2023;22(2):127-144. DOI: 10.1038/s41573-022-00571-8 [Accessed on 2022 Oct 10] PMID: 36216888; PMCID: PMC9549847